JCP January Table of Contents E-Lert


The Journal of Clinical Psychiatry

Volume 74 • Number 1 • January 2013

Listen to an audio summary of this issue Publisher's Podcast: An Audio Summary of This Issue Subscribe to the Podcast
Publisher’s Note
Working Together to Restore the Mental Well-Being of Our Veterans
John S. Shelton
[Purchase] [Full Text]
Marlene P. Freeman and Alan J. Gelenberg
[Purchase] [Full Text]
Original Research
Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40: A Trial Using Equipoise-Stratified Randomization
Hua Jin, Pei-an Betty Shih, Shahrokh Golshan, Sunder Mudaliar, Robert Henry, Danielle K. Glorioso, Stephan Arndt, Helena C. Kraemer, and Dilip V. Jeste
[Abstract] [Full Text] [Audio Summary]
For Clinical Use
  • Caution is needed in long-term use of commonly prescribed atypical antipsychotics (aripiprazole, olanzapine, quetiapine, and risperidone) in middle-aged and older patients with psychotic disorders.
  • When these medications are used, they should be given in low dosages, for short durations, and their side effects should be monitored closely.
  • Shared decision making with patients and their caregivers is recommended, including discussions of risks and benefits of atypical antipsychotics and those of available treatment alternatives.


Trends in Office-Based Treatment of Adults With Stimulants in the United States
Mark Olfson, Carlos Blanco, Shuai Wang, and Laurence L. Greenhill
[Abstract] [Full Text] [Audio Summary]
For Clinical Use
  • Stimulant treatment of adults is increasing, especially among young adults, a population at increased risk of nonmedical stimulant use.
  • Roughly one-half of adult visits to nonpsychiatrist physicians that yield a stimulant prescription include no mental disorder diagnosis.
  • Physicians should consistently document the conditions for which they prescribe stimulants to adults and remain vigilant regarding risks of nonmedical stimulant use.


Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression: A Report From the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) Trial
Ian A. Cook, Aimee M. Hunter, William S. Gilmer, Dan V. Iosifescu, Sidney Zisook, Karl S. Burgoyne, Robert H. Howland, Madhukar H. Trivedi, Rakesh Jain, Scott Greenwald, and Andrew F. Leuchter
[Abstract] [Full Text] [Audio Summary]
For Clinical Use
  • Treatment selection in major depressive disorder could be improved if a biomarker could predict the likelihood and speed of achieving sustained remission with a particular agent for an individual patient.
  • A novel biomarker, based on prefrontal brain electrical activity in the first week of treatment, appears able to predict these clinically relevant aspects of response to treatment in a personalized medicine paradigm.
Depression as a Risk Factor for Diabetes: A Meta-Analysis of Longitudinal Studies
Francesco Rotella and Edoardo Mannucci
[Abstract] [Full Text] [Audio Summary]
For Clinical Use
  • Depressed mood is associated with increased risk of incident diabetes in nondiabetic subjects.
  • The association between depression and diabetes is not entirely mediated by weight gain or the effects of antidepressant drugs.
  • Depression deserves to be included among the risk factors that should drive diabetes screening.
National Network of Depression Centers Position Paper
Electroconvulsive Therapy Device Classification: Response to FDA Advisory Panel Hearing and Recommendations
Richard Weiner, Sarah H. Lisanby, Mustafa M. Husain, Oscar G. Morales, Daniel F. Maixner, Stephen E. Hall, James Beeghly, and John F. Greden, for the National Network of Depression Centers
[Purchase] [Full Text]
CME Article
See the complete CME Activity.
Caring for Returning Veterans: Meeting Mental Health Needs [Commentary]
Terence M. Keane, Basit Chaudhry, John P. Docherty, Robert L. Jesse, Jennifer Lee, Jessica McNurlen, and Eileen Zeller
[Abstract] [Full Text] [Audio Summary]
For Clinical Use
  • Ask patients about their military service and veteran status.
  • Become familiar with veteran resources and eligibility requirements locally and nationally.
  • Equip veterans and their families with education, counseling, and coping mechanisms to deal with mental health issues, including the symptoms of PTSD.
Focus on Childhood and Adolescent Mental Health
New Findings From Longitudinal and Treatment Studies in Youth
Karen Dineen Wagner
[Abstract] [Full Text]


Predictors of Suicide Attempt in Early-Onset, First-Episode Psychoses: A Longitudinal 24-Month Follow-Up Study
Vanessa Sanchez-Gistau, Inmaculada Baeza, Celso Arango, Ana González-Pinto, Elena de la Serna, Mara Parellada, Motserrat Graell, Beatriz Paya, Cloe Llorente, and Josefina Castro-Fornieles
[Abstract] [Full Text] [Audio Summary]
For Clinical Use
  • 12.4% of early-onset first-episode psychosis patients attempted suicide in the 2 years following psychosis onset, the risk being highest in the first year.
  • High risk of suicide at baseline was the best predictor of suicide attempt at follow-up. High risk of suicide at baseline was associated with severe depressive symptoms and with a history of suicide attempt prior to the first-episode psychosis.
  • Neither severity of psychotic symptoms nor affective or nonaffective psychoses diagnostic subtypes were associated with suicidal behavior.


Sleep Problems Among Adolescent Survivors Following the 2008 Wenchuan Earthquake in China: A Cohort Study
Fulei Geng, Fang Fan, Lei Mo, Ian Simandl, and Xianchen Liu
[Abstract] [Full Text] [Audio Summary]
For Clinical Use
  • Sleep problems were common and persistent for up to 30 months among adolescent survivors of the 2008 Wenchuan earthquake.
  • Sleep problems and psychiatric symptoms are not only coexisting but also bidirectional, and multiple demographic, psychosocial, and earthquake-related factors are associated with increased risk and persistence of sleep problems.
  • Early detection of and intervention for sleep problems is important to reduce the impact of natural disasters on health and well-being in adolescent survivors. Exclusives

Practical Psychopharmacology
Drug Interactions in the Treatment of Depression in Patients Receiving β-Blocker Drugs
Chittaranjan Andrade
[Purchase] [Full Text] [Audio Summary]
Clinical Points
  • Some antidepressants inhibit the metabolism of some β-blockers.
  • Bradycardia and hypotension, heart block, or other dose-dependent adverse effects may occur in vulnerable patients as a result of these interactions.
  • Strategies include prescribing an antidepressant that does not affect the metabolism of the β-blocker in use, or prescribing a β-blocker that is not metabolized by the antidepressant in use.
  • If the interaction is unavoidable, the β-blocker dose can be down-titrated using heart rate and blood pressure as a guide.
Original Research
Antipsychotic Drugs, Mood Stabilizers, and Risk of Pneumonia in Bipolar Disorder: A Nationwide Case-Control Study
Shu-Yu Yang, Ya-Tang Liao, Hsing-Cheng Liu, Wei J. Chen, Chiao-Chicy Chen, and Chian-Jue Kuo
[Abstract] [Full Text] [Supplementary Material] [Audio Summary]
Clinical Points
  • Clinicians should be aware that certain second-generation antipsychotics (olanzapine, quetiapine, and risperidone) recommended for first-line monotherapy in bipolar disorder are associated with risk of pneumonia.
  • Lithium has a dose-dependent protective effect against pneumonia and valproic acid shows no risk, which provides evidence for use of both drugs as first-line treatments.
  • Patients with bipolar disorder on combination therapy deserve special clinical attention, particularly those receiving olanzapine plus carbamazepine, or clozapine plus valproic acid, as their risks for pneumonia are high.


Four-Year Outcome in Psychopharmacologically Treated Adults With Attention-Deficit/Hyperactivity Disorder: A Questionnaire Survey
Michael B. Lensing, Pål Zeiner, Leiv Sandvik, and Stein Opjordsmoen
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • This is the first naturalistic outcome study of psychopharmacologically treated adults with attention-deficit/hyperactivity disorder (ADHD) after more than 4 years of observation.
  • Among participants, a majority reported current pharmacologic treatment for ADHD. Adults with ADHD treated for more than 24 months reported more favorable outcome compared to those treated for 24 months or less.
  • Comorbidity at baseline predicted poorer outcome.


Substance-Induced Psychoses Converting Into Schizophrenia: A Register-Based Study of 18,478 Finnish Inpatient Cases
Jussi A. Niemi-Pynttäri, Reijo Sund, Hanna Putkonen, Helena Vorma, Kristian Wahlbeck, and Sami P. Pirkola
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • Substance-induced psychotic disorders predict schizophrenia spectrum disorders to a greater extent than previously thought.
  • More emphasis should be put on provision of clinical follow-up for those patients who have been treated for a diagnosis of substance-induced psychosis.
Focus on Childhood and Adolescent Mental Health
Efficacy and Safety of Quetiapine in Children and Adolescents With Mania Associated With Bipolar I Disorder: A 3-Week, Double-Blind, Placebo-Controlled Trial
Sanjeev Pathak, Robert L. Findling, Willie R. Earley, Larisa D. Acevedo, Jill Stankowski, and Melissa P. DelBello
[Abstract] [Full Text] [Supplementary Material]
Clinical Points
  • This article describes the first large, randomized, placebo-controlled study of the efficacy and safety of quetiapine monotherapy in youth with bipolar I disorder with manic episodes.
  • Quetiapine for 3 weeks at fixed doses of 400 or 600 mg/d was associated with significantly greater improvements in YMRS total score (the primary efficacy measure) compared with placebo, with a rapid onset of effect.
  • Adverse events associated with quetiapine were consistent with its profile in adults with bipolar disorder. The most common adverse events in quetiapine-treated patients included somnolence, sedation, dizziness, and headache.
  • The large population size studied and the broad range of efficacy and safety measures that were investigated support a role for this study in informing clinical practice.


Irritability and Elation in a Large Bipolar Youth Sample: Relative Symptom Severity and Clinical Outcomes Over 4 Years
Jeffrey I. Hunt, Brady G. Case, Boris Birmaher, Robert L. Stout, Daniel P. Dickstein, Shirley Yen, Tina R. Goldstein, Benjamin I. Goldstein, David A. Axelson, Heather Hower, Michael Strober, Neal Ryan, Lance Swenson, David R. Topor, Mary Kay Gill, Lauren M. Weinstock, and Martin B. Keller
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • Compared to bipolar youth with prominent elation symptoms, youth who are diagnosed with bipolar disorder on the basis of episodic irritability experience a similar clinical course but may be at greater risk for depression.
  • Future research on irritability and elation in pediatric bipolar disorder would be aided by more precise assessment of covariation in irritability and elation during and between major mood episodes.
  • Improved characterization of distinct illness courses may enhance the identification and utility of emerging genetic and neuroimaging markers and facilitate development of targeted treatments.
Book Review
Textbook of Psychiatric Epidemiology, 3rd ed
[Abstract] [Full Text]
Free Online Activities
Clinician Perceptions, Expectations, and Management of Negative Symptoms in Schizophrenia [CME]
Stephen R. Marder


MAOIs: Issues in Treatment Adherence and Rates of Treatment Failure [CME]
Lawrence J. Cohen and David A. Sclar


You are receiving this update as a benefit of your membership

To ensure delivery of these messages add to your address book. If you would not like to receive further E-Lerts, go to and click the "Unsubscribe from E-Lerts " link. If you are having trouble unsubscribing, contact the web administrator for assistance

If you are having trouble with your membership, contact our circulation department. Direct any other questions or comments to the web administrator

Please do not reply directly to this e-mail

If you cannot read this go to

Physicians Postgraduate Press, Inc. | 850 Ridge Lake Boulevard, Suite 300 | Memphis, TN 38120

© Copyright 2013, Physicians Postgraduate Press, Inc. All rights reserved